# Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

> **NCT04219540** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 675 (actual)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** XR-B (SUBLOCADETM)
- **DRUG:** XR-NTX

## Key facts

- **NCT ID:** NCT04219540
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-02-28
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04219540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04219540, "Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04219540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*